PH12016501357B1 - Pharmaceutical preparation containing pyridylaminoacetic acid compound - Google Patents
Pharmaceutical preparation containing pyridylaminoacetic acid compoundInfo
- Publication number
- PH12016501357B1 PH12016501357B1 PH12016501357A PH12016501357A PH12016501357B1 PH 12016501357 B1 PH12016501357 B1 PH 12016501357B1 PH 12016501357 A PH12016501357 A PH 12016501357A PH 12016501357 A PH12016501357 A PH 12016501357A PH 12016501357 B1 PH12016501357 B1 PH 12016501357B1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical preparation
- acid compound
- preparation containing
- pyridylaminoacetic acid
- glaucoma
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000004410 intraocular pressure Effects 0.000 abstract 2
- 230000003449 preventive effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 101100243022 Mus musculus Pcnt gene Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- JIEXZSFMUWGAJW-UHFFFAOYSA-N propan-2-yl 2-[[6-[2-(4-pyrazol-1-ylphenyl)-1-(pyridin-3-ylsulfonylamino)ethyl]pyridin-2-yl]amino]acetate Chemical compound CC(C)OC(=O)CNC1=CC=CC(C(CC=2C=CC(=CC=2)N2N=CC=C2)NS(=O)(=O)C=2C=NC=CC=2)=N1 JIEXZSFMUWGAJW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925882P | 2014-01-10 | 2014-01-10 | |
| PCT/JP2015/050366 WO2015105144A1 (ja) | 2014-01-10 | 2015-01-08 | ピリジルアミノ酢酸化合物を含む医薬製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12016501357A1 PH12016501357A1 (en) | 2016-08-15 |
| PH12016501357B1 true PH12016501357B1 (en) | 2020-12-09 |
Family
ID=53520400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016501357A PH12016501357B1 (en) | 2014-01-10 | 2016-07-08 | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US9415038B2 (enExample) |
| EP (3) | EP3424503B1 (enExample) |
| JP (7) | JP5846338B2 (enExample) |
| KR (1) | KR101824829B1 (enExample) |
| CN (2) | CN108743587B (enExample) |
| AU (1) | AU2015205188B2 (enExample) |
| BR (1) | BR112016015763B8 (enExample) |
| CA (1) | CA2936026C (enExample) |
| CL (1) | CL2016001756A1 (enExample) |
| DK (1) | DK3093018T3 (enExample) |
| EA (1) | EA031734B1 (enExample) |
| ES (2) | ES2711091T3 (enExample) |
| GE (1) | GEP20186917B (enExample) |
| HK (1) | HK1223036A1 (enExample) |
| HU (1) | HUE041653T2 (enExample) |
| IL (1) | IL246447B (enExample) |
| MX (1) | MX370361B (enExample) |
| MY (1) | MY163235A (enExample) |
| PH (1) | PH12016501357B1 (enExample) |
| PL (1) | PL3093018T3 (enExample) |
| PT (1) | PT3093018T (enExample) |
| SG (1) | SG11201605653RA (enExample) |
| TR (1) | TR201902019T4 (enExample) |
| TW (1) | TWI598113B (enExample) |
| UA (1) | UA117506C2 (enExample) |
| WO (1) | WO2015105144A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424503B1 (en) * | 2014-01-10 | 2020-09-02 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation including pyridylamino acetic acid compound |
| CA2934612C (en) * | 2014-01-10 | 2021-09-07 | Santen Pharmaceutical Co., Ltd. | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition |
| BR112016015909B1 (pt) | 2014-01-10 | 2020-09-29 | Santen Pharmaceutical Co., Ltd. | Composição farmacêutica contendo composto de ácido piridilaminoacético |
| JP5951922B1 (ja) * | 2014-12-12 | 2016-07-13 | 興和株式会社 | 水性組成物 |
| TWI755356B (zh) * | 2015-07-01 | 2022-02-21 | 日商參天製藥股份有限公司 | 含檸檬酸酯之緩釋劑之用途 |
| JP7032134B2 (ja) | 2015-07-09 | 2022-03-08 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤 |
| WO2018230713A1 (ja) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| JP7250685B2 (ja) * | 2017-09-29 | 2023-04-03 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する医薬 |
| WO2019124487A1 (ja) | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | オミデネパグの組合せ |
| EP3733179A4 (en) | 2017-12-28 | 2021-09-15 | Santen Pharmaceutical Co., Ltd. | PHARMACEUTICAL PREPARATION CONTAINING A PYRIDYLAMINOACETIC ACID COMPOUND |
| MX2020011301A (es) | 2018-04-24 | 2021-01-29 | Allergan Inc | Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002356420A (ja) * | 2001-03-27 | 2002-12-13 | Santen Pharmaceut Co Ltd | 安定な水性液剤 |
| US8648097B2 (en) | 2008-03-12 | 2014-02-11 | Ube Industries, Ltd. | Pyridylaminoacetic acid compound |
| ES2564010T3 (es) * | 2009-03-30 | 2016-03-17 | Ube Industries, Ltd. | Composición farmacéutica para tratar o prevenir el glaucoma |
| JP2011057633A (ja) | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
| US20120202863A1 (en) * | 2011-02-03 | 2012-08-09 | Gerald Horn | Compositions and methods for treatment of glaucoma |
| US9339496B2 (en) * | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
| CA3099517C (en) * | 2012-07-13 | 2022-04-26 | Santen Pharmaceutical Co., Ltd. | Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension |
| JP2014019650A (ja) * | 2012-07-13 | 2014-02-03 | Santen Pharmaceut Co Ltd | スルホンアミド化合物とタフルプロストの組み合わせ |
| US20140018350A1 (en) | 2012-07-13 | 2014-01-16 | Asahi Glass Co., Ltd. | Combination of sulfonamide compound and tafluprost |
| EP3424503B1 (en) * | 2014-01-10 | 2020-09-02 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation including pyridylamino acetic acid compound |
| CA2934612C (en) | 2014-01-10 | 2021-09-07 | Santen Pharmaceutical Co., Ltd. | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition |
| BR112016015909B1 (pt) | 2014-01-10 | 2020-09-29 | Santen Pharmaceutical Co., Ltd. | Composição farmacêutica contendo composto de ácido piridilaminoacético |
-
2015
- 2015-01-08 EP EP18190494.7A patent/EP3424503B1/en not_active Not-in-force
- 2015-01-08 PT PT15735133T patent/PT3093018T/pt unknown
- 2015-01-08 EP EP20183949.5A patent/EP3750541A1/en not_active Withdrawn
- 2015-01-08 PL PL15735133T patent/PL3093018T3/pl unknown
- 2015-01-08 MY MYPI2016001271A patent/MY163235A/en unknown
- 2015-01-08 CA CA2936026A patent/CA2936026C/en active Active
- 2015-01-08 AU AU2015205188A patent/AU2015205188B2/en active Active
- 2015-01-08 KR KR1020167018735A patent/KR101824829B1/ko active Active
- 2015-01-08 SG SG11201605653RA patent/SG11201605653RA/en unknown
- 2015-01-08 EP EP15735133.9A patent/EP3093018B1/en active Active
- 2015-01-08 HU HUE15735133A patent/HUE041653T2/hu unknown
- 2015-01-08 ES ES15735133T patent/ES2711091T3/es active Active
- 2015-01-08 CN CN201811020654.5A patent/CN108743587B/zh active Active
- 2015-01-08 TW TW104100502A patent/TWI598113B/zh active
- 2015-01-08 BR BR112016015763A patent/BR112016015763B8/pt active IP Right Grant
- 2015-01-08 MX MX2016009063A patent/MX370361B/es active IP Right Grant
- 2015-01-08 HK HK16111395.0A patent/HK1223036A1/zh unknown
- 2015-01-08 CN CN201580003994.5A patent/CN105899209B/zh active Active
- 2015-01-08 EA EA201691402A patent/EA031734B1/ru unknown
- 2015-01-08 DK DK15735133.9T patent/DK3093018T3/en active
- 2015-01-08 ES ES18190494T patent/ES2834334T3/es active Active
- 2015-01-08 JP JP2015527691A patent/JP5846338B2/ja active Active
- 2015-01-08 UA UAA201607988A patent/UA117506C2/uk unknown
- 2015-01-08 US US14/592,167 patent/US9415038B2/en active Active
- 2015-01-08 TR TR2019/02019T patent/TR201902019T4/tr unknown
- 2015-01-08 GE GEAP201514239A patent/GEP20186917B/en unknown
- 2015-01-08 WO PCT/JP2015/050366 patent/WO2015105144A1/ja not_active Ceased
- 2015-11-09 JP JP2015219845A patent/JP6491588B2/ja active Active
-
2016
- 2016-06-26 IL IL246447A patent/IL246447B/en active IP Right Grant
- 2016-07-08 PH PH12016501357A patent/PH12016501357B1/en unknown
- 2016-07-08 CL CL2016001756A patent/CL2016001756A1/es unknown
- 2016-07-18 US US15/212,592 patent/US9943510B2/en not_active Ceased
-
2018
- 2018-02-13 US US15/895,100 patent/US10179127B2/en active Active
- 2018-08-28 US US16/114,721 patent/USRE48183E1/en active Active
- 2018-12-06 US US16/211,839 patent/US10702511B2/en active Active
-
2019
- 2019-03-01 JP JP2019037654A patent/JP6785330B2/ja active Active
-
2020
- 2020-05-29 US US16/887,108 patent/US11197849B2/en active Active
- 2020-10-26 JP JP2020178844A patent/JP7087040B2/ja active Active
-
2021
- 2021-11-08 US US17/521,031 patent/US11793798B2/en active Active
-
2022
- 2022-06-08 JP JP2022092999A patent/JP7402922B2/ja active Active
-
2023
- 2023-09-11 US US18/464,646 patent/US12295946B2/en active Active
- 2023-12-11 JP JP2023208468A patent/JP7726542B2/ja active Active
-
2025
- 2025-04-08 US US19/173,125 patent/US20250235439A1/en active Pending
- 2025-07-31 JP JP2025128043A patent/JP2025142352A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501357B1 (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| MX2021004431A (es) | Procesos novedosos. | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| NZ721500A (en) | Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| PH12015501945A1 (en) | Formulations of organic compounds | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MY199237A (en) | Methods of treating ocular conditions | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| EA202191683A1 (ru) | Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии | |
| EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
| MY197518A (en) | Preventive and/or therapeutic agent of immune disease | |
| PL419082A1 (pl) | Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol | |
| EP3187179A4 (en) | Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient |